|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| How Long is Recovery After TURBT? Patient-Reported Outcomes Provide Answers |
| Marshall Strother, MD |
| Ruchika Talwar hosts Marshall Strother for a discussion on the recovery timeline following TURBT for bladder cancer. Utilizing ecological momentary assessment, Dr. Strother's study tracks patient symptoms and recovery in real-time through daily text-based surveys, offering a detailed view of the recovery process. |
|
|
|
|
|
|
|
|
|
|
|
|
Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management
|
Matt Galsky, MD, FASCO, and Neal Shore, MD, FACS
Ashish Kamat hosts a discussion with Matt Galsky and Neal Shore on the latest advancements in bladder cancer treatment, focusing on immunotherapy for advanced bladder cancer and the associated survival benefits. He emphasizes the importance of recognizing and managing immune-related toxicities.
|
|
|
|
|
|
|
|
|
|
|
|
Patient Burdens and Openness to In-Home Intravesical Therapy for Bladder Cancer
|
Amanda Myers, MD, and Timothy Lyon, MD
Sam Chang hosts Amanda Myers and Tim Lyon to discuss the burdens of intravesical therapy for bladder cancer. Dr. Myers shares insights from their study on the patient-reported treatment burdens, revealing significant challenges related to travel, cost, and daily life disruptions due to the current clinic-based treatment setup.
|
|
|
|
|
|
|
|
|
|
|
| Phase 2 Trial: Chemotherapy Plus Immunotherapy Facilitates Bladder Sparing in Muscle-Invasive Bladder Cancer |
| Matthew Galsky, MD |
| Ashish Kamat and Matthew Galsky discuss a phase 2 trial on organ sparing for muscle-invasive bladder cancer, published in Nature Medicine. Dr. Galsky highlights the trial's focus on systemic therapy as an alternative to cystectomy, noting its potential for curative outcomes. |
|
|
|
|
|
|
|
|
|
|
|
| Beyond the Buzzwords: How AI and Advancing Diagnostic Technologies Will Transform Early Bladder Cancer Care
|
|
| The integration of AI and advanced diagnostic technologies in bladder cancer care, particularly for NMIBC, is showing significant promise in improving early diagnosis, risk stratification, and treatment planning. AI can enhance surgical precision, real-time tumor detection, and prediction of recurrence, leading to more personalized and effective treatments. While challenges such as data quality, costs, and regulatory approvals remain, the potential of AI to transform NMIBC care is evident, offering hope for better patient outcomes and more efficient disease management.
|
|
|
|
|
|
| Cretostimogene Grenadenorepvec: At the CORE and Forming BONDs in High-Risk NMIBC and PIVOTing into Intermediate-Risk NMIBC
|
| Zachary Klaassen, MD, MSc, and Rashid Sayyid, MD, MSc
|
| Bladder cancer remains the sixth most commonly diagnosed cancer in the United States, with an estimated 82,290 incident cases in 2023. Because of the persistent recurrence risk of NMIBC in a highly comorbid population, there has been an FDA-led drive towards developing novel treatment options for these patients. The following article will highlight recent advances in this disease space with a specific focus on the oncolytic adenovirus agent cretostimogene grenadenorepvec, and the registration trial in intermediate-risk non-muscle invasive bladder cancer (NMIBC), PIVOT-006.
|
|
|
|
|
|
| State of the Art Lecture: In-Home Therapy for Bladder Cancer |
| Timothy Lyon, MD |
| Timothy Lyon highlights the potential of in-home therapy for bladder cancer, emphasizing the shift driven by the COVID-19 pandemic towards telehealth and same-day discharge procedures. Bladder cancer, particularly non-muscle invasive bladder cancer, has a high burden of treatment, and in-home intravesical therapy could reduce patient workload, improve access, and enhance treatment satisfaction. |
|
|
|
|
|
|
|
|
|
|
| Contemporary Systemic Therapies in Urothelial Carcinoma - Beyond the Abstract |
| JJ H. Zhang, MD & Karim Chamie MD |
| Cisplatin-based chemotherapy remains the standard treatment for muscle-invasive and locally advanced/metastatic urothelial carcinoma, but many patients are ineligible due to various health issues. Immunotherapy, particularly immune checkpoint inhibitors, has emerged as a promising alternative, with several ICIs approved for different stages of treatment, including Atezolizumab and Pembrolizumab for first-line therapy in platinum-ineligible patients, and others like Nivolumab and Avelumab for platinum-refractory cases. |
|
|
|
|
|
| Lessons Learned: What Can Other Disease Sites Teach Us About Practical Implications of Checkpoint Therapy in Urothelial Carcinoma? |
| Sumanta K. Pal, MD |
| Monty Pal highlights that bladder cancer treatment could benefit from lessons learned in other cancers: neoadjuvant therapy may offer superior outcomes compared to adjuvant therapy, optimal sequencing of treatments is crucial, rational drug combinations can enhance efficacy, and maintaining quality of life is essential. These insights emphasize the need for innovative approaches and patient-centered care in advancing urothelial carcinoma treatment. |
|
|
|
|
|
| First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-Paclitaxel Followed by Postsurgical Adjuvant NIVO in Patients with Muscle-Invasive Bladder Cancer |
| Chiara Mercinelli, MD |
| Chiara Mercinelli presented the first results of the NURE-Combo phase 2 study, which evaluated neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC). The combination showed promising results, with 38.7% of patients achieving a pathologic complete response and 73% having a major pathological response, coupled with a high 12-month event-free survival rate of 89.1%. |
|
|
|
|
|
|
|
|
|
|
